MicroPort’s innovative 3rd generation technology, Target Eluting Stent (TES): FIREHAWK that helps coronary arteries of patients heal faster with fewer polymers & less drug load, post angioplasty has made its spectacular entry to India. It ensures a low risk of re-blockage (restenosis) and blood clotting (thrombosis).

1. MicroPort commences local commercial operations in Telangana, with the
World’s innovative technology Target Eluting Stent (TES) for coronary arteries
MicroPort’s innovative 3rd generation technology, Target Eluting Stent (TES): FIREHAWK that
helps coronary arteries of patients heal faster with fewer polymers & less drug load, post
angioplasty has made its spectacular entry to India. It ensures a low risk of re-blockage
(restenosis) and blood clotting (thrombosis). Now, these Stents are available in India and have
been approved in more than 65 hospitals including some premier government and private
hospitals in the country.
So far interventional cardiologists have been using Bare Metal Stents (BMS) or Drug Eluting
Stents (DES) in patients but the availability of Target Eluting Stent (TES) now adds to their
choice of stent selection for better patient care. Interventional cardiologists all over the world

2. are all praises for Target Eluting Stent (TES) that is designed for high quality patient care, faster
recovery and less long term complications.
Mr. Riyaz Desai, the Managing Director, MicroPort India, that manufactures such stents
discussed with media during his visit to Hyderabad, “Cardiovascular diseases, especially
Coronary Heart Disease (CHD), in India is an epidemic. According to the report by the Registrar
General of India, CHD led to 17% of total deaths and 26% of adult deaths in 2001-2003, which
increased to 23% of total and 32% of adult deaths in 2010-2013. The rapidly growing youth and
adult cases of CHD in India beckon for the best quality healthcare products and services.
Citing successful clinical trials, Dr. Martin Leon of USA at a recently held Euro PCR 2017
conference (Paris Course of Re-vascularization) highlighted the influence of “Low TLR rates and
significantly low Def/Prob Stent Thrombosis (ARC defined) with FireHawk in TARGET Clinical
trials.” At the same symposium in Paris, Dr. William Wijns from Europe also shared 3 months
OCT follow-up data of “TARGET ALL Comers” European trial and noted faster healing of
coronary arteries treated by Firehawk: Target Eluting Stent.
“We are very pleased to bring TES to Telangana within 7 months of commencement of our
Indian operations. FIREHAWK, the Target Eluting Stent is approved in more than 26 countries
for sale and is one of the most premium stents in the market. FIREHAWK is truly a generation
beyond Drug Eluting Stent (DES) because of its innovative stent design with low load of
bioabsorbable polymer and drug that is released only towards the vessel walls ( smooth muscle
cells),” adds Mr. Desai.
The proprietary advanced Robotic laser cut & 3D printing technology used in TES creates small
grooves on the surface of the stent strut facing the vessel wall. In these grooves, the drug and
bio-absorbable polymer is impregnated. Target Eluting Stent offers optimal and faster healing,
leading to less chances of re-blockage and stent related blood clot formation (thrombosis) as
seen in TARGET clinical trials.
Millions of lives are improved worldwide through modern innovations and technologies which
are gradually cascading in the Indian market. MicroPort’s entry into the Indian market coincides
with the recent price regulation; however MicroPort continues to penetrate all regions in India
and not just metros. By now FireHawk is approved for sale in more than 65 leading hospitals in
India. Commencement of operations in Telangana is an example of MicroPort’s commitment to
make its world class technologies accessible to all in India.
About MicroPort® MicroPort Scientific Corporation (the "Group") is a leading medical device
company with business focusing on innovating, manufacturing, and marketing high-quality and
high-end medical devices globally. With a diverse portfolio of products now being used at an
average rate of one for every 15 seconds in thousands of major hospitals around the world, the

3. Group maintains world-wide operations in a broad range of business segments including
Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical,
Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a
patient oriented global enterprise improve and reshape patient lives through application of
innovative science and technology. For more information, please refer
www.microportindia.com
MicroPort Scientific India Pvt. Ltd.
801, 215 Atrium II, Behind Courtyard Marriott
Andheri Kurla Road, Andheri (East)
Mumbai 400059
Ph: +91-22-71912900